CHIARADONNA, FERDINANDO
 Distribuzione geografica
Continente #
NA - Nord America 9.051
EU - Europa 7.973
AS - Asia 4.898
SA - Sud America 696
Continente sconosciuto - Info sul continente non disponibili 552
AF - Africa 136
OC - Oceania 16
Totale 23.322
Nazione #
US - Stati Uniti d'America 8.613
SE - Svezia 2.202
IT - Italia 2.094
SG - Singapore 1.699
CN - Cina 1.201
DE - Germania 1.050
RU - Federazione Russa 682
VN - Vietnam 567
BR - Brasile 523
HK - Hong Kong 522
CA - Canada 358
PL - Polonia 345
IE - Irlanda 283
GB - Regno Unito 271
FR - Francia 265
IN - India 172
UA - Ucraina 171
FI - Finlandia 150
BD - Bangladesh 126
NL - Olanda 109
KR - Corea 92
TR - Turchia 92
ID - Indonesia 83
AT - Austria 74
AR - Argentina 68
DK - Danimarca 65
JP - Giappone 52
IQ - Iraq 51
ES - Italia 49
ZA - Sudafrica 49
MX - Messico 46
CH - Svizzera 34
BE - Belgio 32
SA - Arabia Saudita 27
PK - Pakistan 25
EC - Ecuador 24
PH - Filippine 24
IR - Iran 21
UZ - Uzbekistan 21
CO - Colombia 19
MA - Marocco 19
CZ - Repubblica Ceca 18
PT - Portogallo 16
VE - Venezuela 15
JO - Giordania 14
CL - Cile 13
PY - Paraguay 13
TN - Tunisia 13
AU - Australia 12
EG - Egitto 12
TW - Taiwan 12
MY - Malesia 11
NP - Nepal 10
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
PE - Perù 9
UY - Uruguay 9
AZ - Azerbaigian 8
LT - Lituania 8
LU - Lussemburgo 8
AL - Albania 7
JM - Giamaica 7
KE - Kenya 7
KG - Kirghizistan 7
PS - Palestinian Territory 7
ET - Etiopia 6
GR - Grecia 6
HU - Ungheria 6
LB - Libano 6
OM - Oman 6
RO - Romania 6
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
CR - Costa Rica 4
KZ - Kazakistan 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
BO - Bolivia 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
EU - Europa 3
GT - Guatemala 3
HN - Honduras 3
IL - Israele 3
MN - Mongolia 3
NI - Nicaragua 3
SI - Slovenia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
BY - Bielorussia 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
KH - Cambogia 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
Totale 22.750
Città #
Stockholm 1.882
Ann Arbor 1.229
Singapore 1.018
Ashburn 841
Frankfurt am Main 696
Milan 693
San Jose 661
Woodbridge 501
Hong Kong 491
Fairfield 404
Wilmington 342
Chandler 337
Houston 294
Kraków 280
Dublin 275
Dallas 243
New York 222
Toronto 209
Beijing 203
Los Angeles 200
Santa Clara 172
Jacksonville 170
Dearborn 167
Seattle 165
Ho Chi Minh City 160
Hefei 159
Cambridge 146
Munich 132
Chicago 124
The Dalles 121
Hanoi 118
Rome 111
Council Bluffs 93
Seoul 87
Buffalo 86
Princeton 84
Helsinki 77
Lauterbourg 70
Boardman 66
Jakarta 66
Nanjing 62
Shanghai 62
São Paulo 60
Moscow 52
Vienna 51
North Kansas City 50
Dong Ket 49
Guangzhou 45
Columbus 44
Warsaw 44
Lawrence 42
San Diego 41
Montréal 38
Montreal 37
Atlanta 35
Tokyo 35
Bologna 34
Orem 34
Turin 34
Altamura 32
Cento 32
Chennai 31
Denver 31
Johannesburg 31
Brooklyn 30
Brussels 29
Naples 29
Nuremberg 29
Da Nang 28
Lachine 28
Baghdad 25
London 25
Nanchang 25
Poplar 22
Salt Lake City 21
Tianjin 21
Amsterdam 20
Torino 20
Ankara 19
Zhengzhou 19
Zurich 19
Andover 18
Falls Church 18
Figino 18
Paris 18
Hyderabad 17
Manchester 17
Rio de Janeiro 17
Tashkent 17
Florence 16
Kent 16
Brescia 15
Dhaka 15
Phoenix 15
Sacramento 15
San Francisco 15
Boston 14
Brusuglio 14
Kunming 14
Amman 13
Totale 15.112
Nome #
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis 2.776
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 721
Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis 692
Fuzzy modeling and global optimization to predict novel therapeutic targets in cancer cells 538
Design, Synthesis, and Preliminary Biological Evaluation of GlcNAc-6P Analogues for the Modulation of Phosphoacetylglucosamine Mutase 1 (AGM1/PGM3) 507
The Nutrient-Sensing Hexosamine Biosynthetic Pathway as the Hub of Cancer Metabolic Rewiring. 475
Protein Kinase A Activation Promotes Cancer Cell Resistance to Glucose Starvation and Anoikis 473
Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation 462
Central metabolism of functionally heterogeneous mesenchymal stromal cells 415
Mitochondria in Focus: Targeting the Cell-Death Mechanism 402
From cancer metabolism to new biomarkers and drug targets 401
Analysis of mitochondrial metabolism in situ: Combining stable isotope labeling with selective permeabilization 391
Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth 372
RAS and PKA pathways in cancer: new insight from transcriptional analysis 370
Transcriptional profiling of immortalized and K-ras-transformed mouse fibroblasts upon PKA stimulation by forskolin in low glucose availability 369
Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling 346
Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor 345
The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells 344
Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts 338
Ras-dependent carbon metabolism and transformation in mouse fibroblasts 334
Metabolic reprogramming and dysregulated metabolism: Cause, consequence and/or enabler of environmental carcinogenesis? 331
Data recovery and integration from public databases uncovers transformation-specific transcriptional downregulation of cAMP-PKA pathway-encoding genes 329
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: The challenge ahead 320
Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS 311
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies 307
Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response 304
Multi-pathway blood biomarkers to target and monitor multidimensional prevention of cognitive and functional decline (nested in the IN-TeMPO study framed within the world-wide FINGERS network) 302
Integrative transcriptional analysis between human and mouse cancer cells provides a common set of transformation associated genes 297
New Insights into the Connection between Histone Deacetylases, Cell Metabolism, and Cancer 295
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy 293
Acquired glucose sensitivity of k-ras transformed fibroblasts 285
Glutamine deprivation induces abortive S-phase rescued by deoxyribonucleotides in K-ras transformed fibroblasts 285
Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration 284
Genetic and Molecular Characterization of The Human Osteosarcoma 3AB-OS Cancer Stem Cell Line: A Possible Model For Studying Osteosarcoma Origin and Stemness 280
Chiral trimethyl lock based on vicinal disubstituent effect: prolonged release of Camptothecin into cancer cells 279
Cancer Metabolism as a New Real Target in Tumor Therapy 277
Systems biology and the molecular circuits of cancer 274
Towards a systems biology approach to mammalian cell cycle: modeling the entrance into S phase of quiescent fibroblasts after serum stimulation 269
PGM3 inhibition Shows cooperative Effects With Erastin inducing Pancreatic cancer cell death via activation of the Unfolded Protein Response 267
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer 267
PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer 265
Mitochondrial Complex I inhibitors and forced oxidative phosphorylation synergize in inducing cancer cell death 263
PKA stimulation protects K-ras transformed cells from apoptosis induced by glucose depletion reactivating mitochondrial function 262
Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells 261
Hexosamine Pathway inhibition: one molecule able to induce a Brcaness phenotype as promising cancer therapy 258
Vitamin D supplementation and cancer mortality: Narrative review of observational studies and clinical trials 252
Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth 240
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis 235
PGM3 inhibition shows cooperative effects with Erastin inducing pancreatic cancer cell death via activation of the Unfolded Protein Response 228
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis 214
Glucose shortage dependent apoptosis in transformed cells upon activation of UPR-autophagy pathway 210
Itaconate controls its own synthesis via feedback-inhibition of reverse TCA cycle activity at IDH2 209
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy 207
PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect 207
PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells 203
Moving beyond the Tip of the Iceberg: DJ-1 Implications in Cancer Metabolism 184
Hexosamine Biosynthetic Pathway inhibition sensitizes pancreatic cancer cells to DNA damage 184
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy 179
VITAMIN D SUPPLEMENTATION MAY IMPROVE COVID-19 PROGNOSIS? EVIDENCE FROM A SYSTEMATIC REVIEW AND META-ANALYSIS 178
Multicomponent interventions and technologies to reduce the burden of frailty, functional, and cognitive decline: insights from the Age-It Research Program 177
PO-259 Inhibition of the hexosamine biosynthetic pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis 173
Inhibition of the Hexosamine Biosynthetic Pathway Enhances Enzalutamide Response in Prostate Cancer Cells 160
Targeting the Hexosamine Biosynthetic Pathway with a novel PGM3 inhibitor, FR054, to suppress tumour growth and enhance chemotherapy sensitivity in cancer 159
PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells 155
Comparative transcriptional analysis between a K-ras cell model of transformation and the NCI60 human cancer cells collection 146
Hexosamine Biosynthetic Pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage 132
High throughput metabolomics analysis in normal and K-Ras transformed murine fibroblasts 115
PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect 111
Exploiting DNA damage protein O-glycosylation to enhance chemotherapy in pancreatic cancer 105
Targeting Hexosamine Biosynthetic Pathway to Overcome Resistance in Pancreatic Cancer Treatment 103
Exploiting DNA damage response protein O-glycosylation to enhance chemotherapy in pancreatic cancer. 102
Targeting Hexosamine Biosynthetic Pathway to Overcome Resistance in Pancreatic Cancer Treatment 102
Inhibition of HBP by targeting PGM3 enzyme as new anticancer therapy 100
PGM3 inhibition shows cooperative effects with erastin inducing pancreatic cancer cell death via activation of the unfolded protein response 93
PGM3 inhibition shows cooperative effects with erastin inducing pancreatic cancer cell death via activation of the unfolded protein response 83
Hexosamine biosynthetic pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage 81
Histone glycation: a novel epigenetic target in breast cancer 59
Totale 23.322
Categoria #
all - tutte 61.376
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.376


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.055 107 94 124 110 87 91 59 43 53 43 101 143
2022/20231.440 157 403 162 156 104 183 11 78 102 6 59 19
2023/2024975 24 38 27 79 100 217 203 44 65 34 23 121
2024/20253.104 176 254 296 141 214 140 255 156 265 447 307 453
2025/202611.137 737 466 768 940 1.139 852 1.225 357 848 2.608 508 689
2026/2027313 313 0 0 0 0 0 0 0 0 0 0 0
Totale 23.322